Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Disease Markers

Volumn 2017, Issue , 2017, Pages

  Cha, Yoon Jin ^a   Jung, Woo Hee ^a   Koo, Ja Seung ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOGLUCONOLACTONASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; OXIDOREDUCTASE; PHOSPHOGLUCONATE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 6-PHOSPHOGLUCONOLACTONASE; CARBOXYLESTERASE; ERBB2 PROTEIN, HUMAN; KI 67 ANTIGEN; NFE2L2 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OVERALL SURVIVAL; PENTOSE PHOSPHATE CYCLE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; AGED; BONE; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; TREATMENT OUTCOME;

AGED; BONE AND BONES; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARBOXYLIC ESTER HYDROLASES; CARCINOMA, DUCTAL, BREAST; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; NF-E2-RELATED FACTOR 2; PENTOSE PHOSPHATE PATHWAY; PHENOTYPE; PHOSPHOGLUCONATE DEHYDROGENASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RISK FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 85013287203     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2017/7062517     Document Type: Article

References (36)

1. C. Riganti, E. Gazzano, M. Polimeni, E. Aldieri, and D. Ghigo, "The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate," Free Radical Biology andMedicine, vol. 53, no. 3, pp. 421-436, 2012.
2. C. Zhang, Z. Zhang, Y. Zhu, and S.Qin, "Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer," Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 2, pp. 280-289, 2014.
3. G. Lucarelli, V. Galleggiante, M. Rutigliano et al., "Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma," Oncotarget, vol. 6, no. 15, pp. 13371-13386, 2015.
4. E. C. Woodhouse, R. F. Chuaqui, and L. A. Liotta, "General mechanisms of metastasis," Cancer, vol. 80, S8, pp. 1529-1537, 1997.
5. R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg, "Breast cancer metastasis to the central nervous system," American Journal of Pathology, vol. 167, no. 4, pp. 913-920, 2005.
6. H. Abali and I. Çelik, "High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel," American Journal of Clinical Oncology, vol. 25, no. 6, pp. 632-633, 2002.
7. M. Colleoni, A. O'Neill, A. Goldhirsch et al., "Identifying breast cancer patients at high risk for bone metastases," Journal of Clinical Oncology, vol. 18, no. 23, pp. 3925-3925, 2000.
8. A. J. Evans, J. J. James, E. J. Cornford et al., "Brain metastases from breast cancer: identification of a high-risk group," Clinical Oncology (Royal College of Radiologists), vol. 16, no. 5, pp. 345- 349, 2004.
9. D. G. Hicks, S. M. Short, N. L. Prescott et al., "Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR," American Journal of Surgical Pathology, vol. 30, no. 9, pp. 1097-1104, 2006.
10. T. Lorincz, J. Tóth, G. Badalian, J. Tímár, and M. Szendroi, "HER-2/neu genotype of breast cancer may change in bone metastasis," Pathology and Oncology Research, vol. 12, no. 3, pp. 149-152, 2006.
11. J. Gaedcke, F. Traub, S. Milde et al., "Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer," Modern Pathology, vol. 20, no. 8, pp. 864-870, 2007.
12. G. L. Nicolson, "Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites," Cancer and Metastasis Review, vol. 7, no. 2, pp. 143-188, 1988.
13. S. Paget, "Thedistribution of secondary growths in cancer of the breast," The Lancet, vol. 133, no. 3421, pp. 571-573, 1889.
14. T. Hasebe, S. Imoto, T. Yokose, G.-I. Ishii, M. Iwasaki, and N.Wada, "Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study," Human Pathology, vol. 39, no. 5, pp. 681-693, 2008.
15. B. Wei, J. Wang, P. Bourne et al., "Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas," Human Pathology, vol. 39, no. 12, pp. 1809-1815, 2008.
16. C. W. Elston and I. O. Ellis, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup," Histopathology, vol. 19, no. 5, pp. 403-410, 1991.
17. Hammond, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer," Journal of Clinical Oncology, vol. 28, no. 16, pp. 2784-2795, 2010.
18. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer," Journal of Clinical Oncology, vol. 25, no. 1, pp. 118-145, 2007.
19. K. Y. Won, G. Y. Kim, Y. W. Kim, J. Y. Song, and S.-J. Lim, "Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer," Human Pathology, vol. 41, no. 1, pp. 107-112, 2010.
20. A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann, and H.-J. Senn, "Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011," Annals of Oncology, vol. 22, no. 8, pp. 1736- 1747, 2011.
21. S. Manandhar, B.-H. Choi, K.-A. Jung et al., "NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity," Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1773-1785, 2012.
22. F. Ahmad, D. Dixit, V. Sharma et al., "Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma," Cell Death & Disease, vol. 7, Article IDe2213, 2016.
23. B. Polásková and E. Slezáková, "Our experience with reeducation in aphasia,"ActaUniversitatis PalackianaeOlomucensis Facultatis Medicae, vol. 121, pp. 179-187, 1989.
24. J. R.Dusick, T. C. Glenn,W.N. P. Lee et al., "Increased pentose phosphate pathway flux after clinical traumatic brain injury: a [1,2-13C2]glucose labeling study in humans," Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 9, pp. 1593-1602, 2007.
25. C. P.Ramsey, C. A. Glass, M. B. Montgomery et al., "Expression of Nrf2 in neurodegenerative diseases," Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75-85, 2007.
26. S. Jiang,Y.Yang, T. Li et al., "Anoverviewof themechanisms and novel roles of Nrf2 in cardiovascular diseases," Expert Opinion on Therapeutic Targets, vol. 20, no. 12, pp. 1413-1424, 2016.
27. S. Homma, Y. Ishii, Y. Morishima et al., "Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer," Clinical Cancer Research, vol. 15, no. 10, pp. 3423-3432, 2009.
28. H. J. Kang, Y. W. Yi, Y. B. Hong et al., "HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction," Scientific Reports, vol. 4, article 7201, 2014.
29. P.-L. Lin, J. T. Chang, D.-W. Wu, C.-C. Huang, and H. Lee, "Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4," Free Radical Biology and Medicine, vol. 95, pp. 121-132, 2016.
30. X. Wang, X. Li, X. Zhang et al., "Glucose-6-phosphate dehydrogenase expression is correlated with poor clinical prognosis in esophageal squamous cell carcinoma," European Journal of Surgical Oncology, vol. 41, no. 10, pp. 1293-1299, 2015.
31. K. Ahopelto, C. Böckelman, J. Hagström, S. Koskensalo, and C. Haglund, "Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer," Cancer Biology andTherapy, vol. 17, no. 2, pp. 163-168, 2016.
32. C. A. Lange, J. Tisch-Rottensteiner, D. Böhringer, G. Martin, J. Schwartzkopff, and C. Auw-Haedrich, "Enhanced TKTL1 expression in malignant tumors of the ocular adnexa predicts clinical outcome," Ophthalmology, vol. 119, no. 9, pp. 1924-1929, 2012.
33. S. Elf, R. Lin, S. Xia et al., "Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin," Oncogene, vol. 36, no. 2, pp. 254-262, 2017.
34. D. Catanzaro, E. Gaude, G. Orso et al., "Inhibition of glucose-6- phosphate dehydrogenase sensitizes cisplatin-resistant cells to death," Oncotarget, vol. 6, no. 30, pp. 30102-30114, 2015.
35. X. Wang, G. Wu, G. Cao et al., "Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras- TAp73-G6PD axis in bladder cancer cells," Molecular Medicine Reports, vol. 12, no. 3, pp. 4620-4625, 2015.
36. L. Li, M. A. Fath, P. M. Scarbrough, W. H. Watson, and D. R. Spitz, "Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer," Redox Biology, vol. 4, pp. 127-135, 2015.